Anavex Life Sciences Corp
Chiusa
SettoreSettore sanitario
2.41 2.55
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
2.31
Massimo
2.43
Entrata | 14M 7.8M |
|---|---|
EPS | 0.08 |
Dipendenti | 34 |
EBITDA | 3.3M -3.2M |
Utili prossimi | 24 nov 2026 |
|---|
Capitalizzazione di Mercato | -47M 241M |
|---|---|
Apertura precedente | -0.14 |
Chiusura precedente | 2.41 |
Notizie sul Sentiment di mercato
By Acuity
41%
59%
103 / 339 Classifica in Healthcare
Anavex Life Sciences Corp Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Notizie correlate
Confronto tra pari
Modifica del prezzo
Anavex Life Sciences Corp Previsione
Sentiment
By Acuity
103 / 339 Classifica in Settore sanitario
Notizie sul Sentiment di mercato
Prove rialziste
Volatilità
Sotto la media
Volume delle notizie (RCV)
Sotto la media
Notizie finanziarie
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$
Chi Siamo Anavex Life Sciences Corp
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.